FOR SUPPORT, CALL 1-866-APF-3635 (273-3635)
Interested in learning more? The American Porphyria Foundation will share details of the study and connect EPP and XLP patients (Ages 12-75) with a study site for the Mitsubishi Phase 3 clinical trial for MT-7117.
New study site locations at Porphyria Centers have recently been added, including:
Patients can also participate at the following study sites:
1. Wake Forest Baptist (Dr. H. Bonkovsky) - Winston Salem, NC
2. Kansas City, MO (Dr. B. Freilich)
If you are interested in learning more, please contact Edrin Williams, Director of Patient Services; he will connect you with a research coordinator.
Phone: 301-312-8741 E-mail: edrinw@porphyriafoundation.org
CLINICAL TRIAL INFORMATION
Trial Description: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, And Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Treatment: Oral medication (pills), once daily in the morning with or without food Duration: 26 weeks plus optional 26-week double-blinded extension.
Endpoint: Increased pain-free light exposure in adults and adolescents with a history of phototoxic reactions from EPP or XLP.
Study Sites: There will be 12 study sites in the US, followed by global study sites across multiple countries.
Age Range: Patients age 12 - 75
Travel: Will be included and will be arranged by a concierge service trained on EPP/XLP (including travel, necessary hotels, transportation, food). A small stipend will also be offered for each study site visit.
We look forward to hearing from you!
If you have already been in contact with the APF regarding the clinical trial, you will be referred to your preferred study site when active.
?If you would like to consider changing study sites, please contact edrin@porphyriafoundation.org or call 301-347-7166
